GEN Exclusives

More »

GEN News Highlights

More »
Jul 1, 2008

Lonza Reports Manufacturing Deal with Osiris and Facility Constructions

  • Lonza signed a clinical and commercial manufacturing agreement with Osiris Therapeutics for Prochymal®, Osiris’ adult stem cell therapy. Prochymal is being evaluated in Phase III trials for acute and steroid-refractory graft-versus-host disease and Crohn's disease.

    Lonza also announced the construction of new facilities including the first commercial-scale allogeneic cGMP manufacturing plant and additional capacity to produce cGMP-grade cell culture media for therapeutic applications. This will provide Lonza the capacity to manufacture the tens of billions of cells per day needed to support its clients’ commercialization efforts, say Lonza officials.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Children and Antipsychotic Drugs

Do you think children and adolescents with behavioral problems are overmedicated?